Focused On-demand Library for Glucose-6-phosphate isomerase

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.







Alternative names:

Autocrine motility factor; Neuroleukin; Phosphoglucose isomerase; Phosphohexose isomerase; Sperm antigen 36

Alternative UPACC:

P06744; B4DG39; Q9BRD3; Q9BSK5; Q9UHE6


Glucose-6-phosphate isomerase, known by alternative names such as Autocrine motility factor, Neuroleukin, and Phosphohexose isomerase, plays a crucial role in glycolysis and gluconeogenesis by catalyzing the conversion of glucose-6-phosphate to fructose-6-phosphate. Beyond its enzymatic functions, it serves as a cytokine influencing angiogenesis, neurotrophic activities, and immunoglobulin secretion.

Therapeutic significance:

The protein's deficiency is linked to Hemolytic anemia, non-spherocytic, due to glucose phosphate isomerase deficiency, highlighting its critical role in metabolic pathways. Understanding the multifaceted functions of Glucose-6-phosphate isomerase could pave the way for innovative therapeutic strategies targeting metabolic disorders and beyond.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.